Crossmark

Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan

Crossref DOI link: https://doi.org/10.1007/s10198-026-01912-9

Published Online: 2026-03-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nusawat, Chanon https://orcid.org/0009-0009-2716-3727
Sato, So https://orcid.org/0000-0003-1265-6835
Taniguchi, Jumpei https://orcid.org/0000-0003-2480-9018
Kimura, Yuya https://orcid.org/0000-0003-1649-0596
Yasunaga, Hideo https://orcid.org/0000-0002-6017-469X
Funding

Funding for this research was provided by:

The University of Tokyo
License Information

Text and Data Mining valid from 2026-03-04

Version of Record valid from 2026-03-04
More Information

Article History

Received: 2 June 2025

Accepted: 11 February 2026

First Online: 4 March 2026